Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
The application is supported by data from EPCORE™ NHL-1 Phase 1/2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in patients with relapsed, progressive or refractory ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
European Medicines Agency (EMA) validates AbbVie's Marketing Authorization Application; Genmab submits Biologics License Application to U.S. Food and Drug Administration (FDA) The submissions are ...
T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalitiesCizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseasesOver 60 ...
Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback